Featured Research

from universities, journals, and other organizations

Antiviral Treatment For Hepatitis B: Early Detection Of Lamivudine-resistant Mutants

Date:
January 16, 2008
Source:
World Journal of Gastroenterology
Summary:
Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and advanced liver diseases. However, long-term lamivudine monotherapy leads to the emergence of lamivudine-resistant hepatitis B virus (HBV) mutants in some patients chronically infected with HBV. Sensitive methods for early detection of lamivudine-resistant mutants will help physicians make clinical decisions in treating patients with HBV infection.Suitable methods are necessary for diagnosis of resistance in the clinical setting to detect low abundant lamivudine-resistant mutants in lamivudine treated patients as early as possible.

Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and advanced liver diseases. However, long-term lamivudine monotherapy leads to the emergence of lamivudine-resistant hepatitis B virus (HBV) mutants in some patients chronically infected with HBV. Sensitive methods for early detection of lamivudine-resistant mutants will help physicians make clinical decisions in treating patients with HBV infection.

To date, many assays have been used for detection of lamivudine-resistant mutants in patients with Hepatitis B. Differences in sensitivity, specificity, cost, and time required, exist in these methods. Real-time PCR is able to quantitatively detect a small portion of resistant mutants in HBV populations and ligase detection reaction (LDR) is a newly developed method for detection of low abundant mutants in the background of wild-type HBV. However, there are no studies which have compared the clinical performance of the two methods.

A new research article addresses this question. It compared LDR and real-time PCR for detection of low abundant YMDD mutations in mixed plasmids and serum samples from 52 lamivudine treated patients. Time required and reagent cost for both assays were evaluated. The research was conducted carefully by an experienced team of investigators.

The article suggested both methods are sensitive and inexpensive for detection of YMDD mutation; but LDR is more sensitive than real-time PCR. The results obtained with both methods were completely concordant in all serum samples. LDR was able to detect as low as 0.01% (100 copies/mL) of YIDD plasmid, while real-time PCR only detected 0.1% (1000 copies/mL) of YIDD plasmid in the background of YMDD plasmid. In addition, the cost of LDR is slightly lower than that of real-time PCR.

However, real-time PCR is much more rapid and requires less manual work than LDR. The total assay time for LDR and real-time PCR was 4.5 and 2.5 h, respectively. Another advantage of the real-time PCR method is it is able to calculate the ratio of mutants to total virus in samples. This will be useful in clinical studies on the dynamics of resistant mutants during lamivudine therapy.

Journal reference: Wang XL, Xie SG, Zhang L, Yang WX, Wang X, Jin HZ. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(1): 120-124 http://www.wjgnet.com/1007-9327/14/120.asp


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Cite This Page:

World Journal of Gastroenterology. "Antiviral Treatment For Hepatitis B: Early Detection Of Lamivudine-resistant Mutants." ScienceDaily. ScienceDaily, 16 January 2008. <www.sciencedaily.com/releases/2008/01/080116093512.htm>.
World Journal of Gastroenterology. (2008, January 16). Antiviral Treatment For Hepatitis B: Early Detection Of Lamivudine-resistant Mutants. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2008/01/080116093512.htm
World Journal of Gastroenterology. "Antiviral Treatment For Hepatitis B: Early Detection Of Lamivudine-resistant Mutants." ScienceDaily. www.sciencedaily.com/releases/2008/01/080116093512.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins